ACT225 Biotherapeutics
Precision theanostics for imaging and therapy of local and advanced cancers
We Are Visionaries
Transforming the future of health care with our innovative theranostic technology.
At ACT225 Biotherapeutics, we are pioneering the future of targeted cancer treatment with Actinium-225, a powerful alpha-emitting radioisotope. Our cutting-edge approach harnesses the precision of targeted alpha therapy (TAT) to selectively destroy cancer cells while minimizing damage to healthy tissue. By integrating advanced radiopharmaceutical development with innovative imaging solutions, we are transforming the way local and advanced cancers are diagnosed and treated. Our mission is to enhance patient outcomes through safer, more effective, and highly targeted therapies, bringing new hope to those battling cancer.
1
Gene Therapy
12 ONGOING RESEARCH PROJECTS
Use this space to promote the business, its products or its services. Help people become familiar with the business and its offerings, creating a sense of connection and trust. Focus on what makes the business unique and how users can benefit from choosing it.
2
Oncology
5 ONGOING RESEARCH PROJECTS
Use this space to promote the business, its products or its services. Help people become familiar with the business and its offerings, creating a sense of connection and trust. Focus on what makes the business unique and how users can benefit from choosing it.
3
Drug Discovery & Delivery
8 ONGOING RESEARCH PROJECTS
Use this space to promote the business, its products or its services. Help people become familiar with the business and its offerings, creating a sense of connection and trust. Focus on what makes the business unique and how users can benefit from choosing it.
Use this space to share a testimonial quote about the business, its products or its services. Insert a quote from a real customer or client here to build trust and win over site visitors.
Dr. Humphery Fonge
CEO and Co-Founder
Dr. Maruti Uppalapati
CEO and Co-Founder
